Search results for "target"

showing 10 items of 1196 documents

Yeast Translation Elongation Factor eIF5A Expression Is Regulated by Nutrient Availability through Different Signalling Pathways

2020

Translation elongation factor eIF5A binds to ribosomes to promote peptide bonds between problematic amino acids for the reaction like prolines. eIF5A is highly conserved and essential in eukaryotes, which usually contain two similar but differentially expressed paralogue genes. The human eIF5A-1 isoform is abundant and implicated in some cancer types

MitochondrionBiotecnologialcsh:ChemistryPeptide Initiation FactorsGene Expression Regulation Fungalmitochondrial respirationGene expressionExpressió genèticaHap1Protein Isoformshemelcsh:QH301-705.5SpectroscopyChemistryRNA-Binding ProteinsTranslation (biology)Iron DeficienciesGeneral MedicineTORAerobiosisUp-RegulationComputer Science ApplicationsCell biologySnf1EIF5ASignal TransductionGene isoformSaccharomyces cerevisiae ProteinsIronCitric Acid CycleDown-RegulationSaccharomyces cerevisiaeMechanistic Target of Rapamycin Complex 1Models BiologicalArticleCatalysisInorganic ChemistryeIF5APhysical and Theoretical ChemistryMolecular BiologyTranscription factorGeneLysineOrganic ChemistryNutrientsMetabolismCarbonMetabolic Flux AnalysisGlucoselcsh:Biology (General)lcsh:QD1-999Fermentationgene expressionInternational Journal of Molecular Sciences
researchProduct

Conformational control of Bax localization and apoptotic activity by Pro168.

2004

In healthy cells, Bax resides inactive in the cytosol because its COOH-terminal transmembrane region (TMB) is tucked into a hydrophobic pocket. During apoptosis, Bax undergoes a conformational change involving NH2-terminal exposure and translocates to mitochondria to release apoptogenic factors. How this process is regulated remains unknown. We show that the TMB of Bax is both necessary and sufficient for mitochondrial targeting. However, its availability for targeting depends on Pro168 located within the preceding loop region. Pro168 mutants of Bax lack apoptotic activity, cannot rescue the apoptosis-resistant phenotype of Bax/Bak double knockout cells, and are retained in the cytosol even…

Models MolecularConformational changeProlineCell SurvivalProtein ConformationMutantMolecular Sequence DataApoptosisMitochondrionMitochondrial apoptosis-induced channelArticleCell Line03 medical and health sciencesMice0302 clinical medicineBcl-2-associated X proteinProto-Oncogene ProteinsAnimalsHumansAmino Acid Sequence030304 developmental biologybcl-2-Associated X Proteinapoptosis; Bcl-2 family; NH2-terminal exposure; mitochondria; targeting0303 health sciencesbiologyMembrane ProteinsCell BiologyPeptide FragmentsCell biologyTransport proteinMitochondriaCytosolProtein Transportbcl-2 Homologous Antagonist-Killer ProteinProto-Oncogene Proteins c-bcl-2030220 oncology & carcinogenesisbiology.proteinBcl-2 Homologous Antagonist-Killer ProteinHeLa CellsThe Journal of cell biology
researchProduct

Ligand-binding domain determines endoplasmic reticulum exit of AMPA receptors.

2010

AMPA receptors (AMPARs) are tetrameric ion channels that mediate rapid glutamate signaling in neurons and many non-neuronal cell types. Endoplasmic reticulum (ER) quality control mechanisms permit only correctly folded functional receptors to be delivered to the cell surface. We analyzed the biosynthetic maturation and transport of all 12 GluA1–4 subunit splice variants as homomeric receptors and observed robust isoform-dependent differences in ER exit competence and surface expression. In contrast to inefficient ER exit of both GluA3 splice forms and the flop variants of GluA1 and GluA4, prominent plasma membrane expression was observed for the other AMPAR isoforms. Surprisingly, deletion …

Models MolecularProtein ConformationImmunoblottingMolecular Sequence DataAMPA receptorBiologymedicine.disease_causeEndoplasmic ReticulumLigandsBiochemistryCell membrane03 medical and health sciences0302 clinical medicineNeurobiologyProtein targetingChlorocebus aethiopsmedicineHomomericAnimalsHumansProtein IsoformsAmino Acid SequenceReceptors AMPAReceptorMolecular BiologyIon channel030304 developmental biology0303 health sciencesBinding SitesSequence Homology Amino AcidEndoplasmic reticulumCell MembraneCell BiologyCell biologyTransport proteinProtein Structure TertiaryAlternative SplicingProtein SubunitsProtein Transportmedicine.anatomical_structureHEK293 CellsMicroscopy FluorescenceCOS CellsProtein Multimerization030217 neurology & neurosurgeryThe Journal of biological chemistry
researchProduct

Assessing model accuracy using the homology modeling automatically software

2007

Homology modeling is a powerful technique that greatly increases the value of experimental structure determination by using the structural information of one protein to predict the structures of homologous proteins. We have previously described a method of homology modeling by satisfaction of spatial restraints (Li et al., Protein Sci 1997;6:956-970). The Homology Modeling Automatically (HOMA) web site,http://www-nmr.cabm.rutgers.edu/HOMA, is a new tool, using this method to predict 3D structure of a target protein based on the sequence alignment of the target protein to a template protein and the structure coordinates of the template. The user is presented with the resulting models, togeth…

Models MolecularProtein Conformationbusiness.industryProteinsSequence alignmentStructure validationComputational biologyProtein superfamilyMachine learningcomputer.software_genreBiochemistryHomology (biology)Structural genomicsProtein structureStructural BiologyArtificial intelligenceTarget proteinHomology modelingbusinessMolecular BiologycomputerSoftwareMathematicsProteins: Structure, Function, and Bioinformatics
researchProduct

Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells.

2020

Models MolecularProto-Oncogene Proteins B-rafProtein ConformationMutantMutation MissenseDermatologyInhibitory Concentration 50Structure-Activity RelationshipCell Line TumormedicineHumansPoint MutationMolecular Targeted TherapyPrecision MedicineMelanomaProtein Kinase InhibitorsDose-Response Relationship Drugbusiness.industryMelanomaDrug Repositioningmedicine.diseaseNeoplasm ProteinsBRAF V600EMolecular Docking SimulationAmino Acid SubstitutionDrug DesignCancer researchIdentification (biology)Drug Screening Assays AntitumorbusinessJournal of the American Academy of Dermatology
researchProduct

Indicaxanthin, a multi-target natural compound from Opuntia ficus-indica fruit: From its poly-pharmacological effects to biochemical mechanisms and m…

2019

Abstract Over the latest years phytochemical consumption has been associated to a decreased risk of both the onset and the development of a number of pathological conditions. In this context indicaxanthin, a betalain pigment from Opuntia ficus-indica fruit, has been the object of sound research. Explored, at first, for its mere antioxidant potential, Indicaxanthin is now regarded as a redox-active compound able to exert significant poly-pharmacological effects against several targets in a number of experimental conditions both in vivo and in vitro. This paper aims to provide an overview on the therapeutical effects of indicaxanthin, ranging from the anti-inflammatory to the neuro-modulatory…

Models MolecularPyridinesOpuntia ficusPhytochemicalsContext (language use)Antioxidant potential01 natural sciencesMiceStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compoundMulti targetCell Line TumorNeoplasmsSettore BIO/10 - BiochimicaBetalainDrug DiscoveryAnimalsHumansCell Proliferation030304 developmental biologyInflammationIndicaxanthin Multi-target compound Poly-pharmacology Antioxidant Antiinflammatory Antitumoral Antiproliferative Neuromodulator Molecular modellingPharmacologyBiological Products0303 health sciencesDose-Response Relationship DrugMolecular StructureTraditional medicine010405 organic chemistryNatural compoundOrganic ChemistryOpuntiaGeneral MedicineAntineoplastic Agents PhytogenicSettore CHIM/08 - Chimica FarmaceuticaBetaxanthins0104 chemical sciencesMice Inbred C57BLNeuroprotective AgentsPhytochemicalchemistryBlood-Brain BarrierFruitDrug Screening Assays AntitumorIndicaxanthinEuropean Journal of Medicinal Chemistry
researchProduct

IKK-β inhibitors: An analysis of drug–receptor interaction by using Molecular Docking and Pharmacophore 3D-QSAR approaches

2010

Abstract The IKK kinases family represents a thrilling area of research because of its importance in regulating the activity of NF-kB transcription factors. The discovery of the central role played by IKK-β in the activation of transcription in response to apoptotic or inflammatory stimuli allowed to considerate its modulation as a promising tool for the treatment of chronic inflammation and cancer. To date, several IKK-β inhibitors have been discovered and tested. In this work, an analysis of the interactions between different classes of inhibitors and their biological target was performed, through the application of Molecular Docking and Pharmacophore/3D-QSAR approaches to a set of 141 in…

Models MolecularQuantitative structure–activity relationshipReceptors DrugMolecular Sequence DataQuantitative Structure-Activity RelationshipIκB kinaseComputational biologyPharmacologyBiologyMaterials ChemistryHumansAmino Acid SequenceNF-kBHomology modelingPhysical and Theoretical ChemistryProtein Kinase InhibitorsTranscription factorSpectroscopyIKK-betaIKK-beta inhibitors Molecular Docking Pharmacophore 3D-QSAR approachesBinding SitesPharmacophoreKinaseHomology modelingSettore CHIM/08 - Chimica FarmaceuticaComputer Graphics and Computer-Aided DesignI-kappa B KinaseMolecular DockingStructural Homology ProteinBiological targetDrug receptorPharmacophoreJournal of Molecular Graphics and Modelling
researchProduct

Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive b…

2021

Abstract Breast Cancer (BC) is a leading cause of death in women, currently affecting 13% of female population worldwide. First-line clinical treatments against Estrogen Receptor positive (ER+) BC rely on suppressing estrogen production, by inhibiting the aromatase (AR) enzyme, or on blocking estrogen-dependent pro-oncogenic signaling, by targeting Estrogen Receptor (ER) α with selective Modulators/Degraders (SERMs/SERDs). The development of dual acting molecules targeting AR and ERα represents a tantalizing alternative strategy to fight ER + BC, reducing the incidence of adverse effects and resistance onset that limit the effectiveness of these gold-standard therapies. Here, in silico desi…

Molecular dynamicAntineoplastic Agents Hormonalmedicine.drug_classIn silicoEstrogen receptorBreast NeoplasmsMolecular dynamicsQM/MMBreast cancerbreast cancerDrug DiscoverymedicineHumansAromataseIC50Pharmacologychemistry.chemical_classificationbiologyAromatase InhibitorsMultitargetOrganic ChemistryEstrogen AntagonistsAromatase inhibitorGeneral Medicinemedicine.diseaseSERMEnzymechemistryEstrogenCell cultureSettore CHIM/03 - Chimica Generale E InorganicaSERDbiology.proteinCancer researchFemale
researchProduct

Suitability ofMMGBSAfor the selection of correct ligand binding modes from docking results

2018

The estimation of the correct binding mode and affinity of a ligand into a target protein using computational methods is challenging. However, docking can introduce poses from which the correct binding mode could be identified using other methods. Here, we analyzed the reliability of binding energy estimation using the molecular mechanics-generalized Born surface area (MMGBSA) method without and with energy minimization to identify the likely ligand binding modes within docking results. MMGBSA workflow (a) outperformed docking in recognizing the correct binding modes of androgen receptor ligands and (b) improved the correlation coefficient of computational and experimental results of rescor…

Molecular modelBinding energyta3111LigandsEnergy minimization01 natural sciencesBiochemistrylääkesuunnitteluSubstrate SpecificityCytochrome P-450 CYP2A6Free energy perturbationCoumarinsDrug DiscoveryHumansta317PharmacologyBinding Sitesmolecular modeling010405 organic chemistryChemistryDrug discoveryOrganic Chemistryta1182liganditreceptor and ligandslaskennallinen kemiaLigand (biochemistry)Protein Structure Tertiary0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistryDocking (molecular)structure based drug-designThermodynamicsMolecular MedicineproteiinitTarget proteinBiological systemProtein BindingChemical Biology & Drug Design
researchProduct

Evolutionary dynamics of imatinib-treated leukemic cells by stochastic approach

2008

The evolutionary dynamics of a system of cancerous cells in a model of chronic myeloid leukemia (CML) is investigated by a statistical approach. Cancer progression is explored by applying a Monte Carlo method to simulate the stochastic behavior of cell reproduction and death in a population of blood cells which can experience genetic mutations. In CML front line therapy is represented by the tyrosine kinase inhibitor imatinib which strongly affects the reproduction of leukemic cells only. In this work, we analyze the effects of a targeted therapy on the evolutionary dynamics of normal, first-mutant and cancerous cell populations. Several scenarios of the evolutionary dynamics of imatinib-tr…

Monte Carlo simulation stochastic approach Evolutionary dynamicsMutation rate87.23.kgmedicine.drug_classQC1-999medicine.medical_treatmentPopulationGeneral Physics and AstronomyBiologyTyrosine-kinase inhibitorTargeted therapyhemic and lymphatic diseasesmedicine87.10.mncomplex systemsQuantitative Biology - Populations and EvolutioneducationEvolutionary dynamicseducation.field_of_studycancer evolutionPhysicsstochastic dynamics87.19.xjPopulations and Evolution (q-bio.PE)Myeloid leukemiaImatinibSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)FOS: Biological sciencesCancer cellCancer research87.10.rtmedicine.drugOpen Physics
researchProduct